Dr TEOH Yuen Chun Jeremy    
張源津

Associate Professor
MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery)

Urology
(852) 3505 2625 / Appointment 3505 2954
jeremyteohadd this for spam@add this for spamsurgery.cuhk.edu.hk
@jteoh_hk
H-5184-2016
0000-0002-9361-2342

Biography

Dr Jeremy Teoh is currently the Assistant Dean (External Affairs) and Associate Professor of the Faculty of Medicine, The Chinese University of Hong Kong (CUHK). He is also the Director of Urology Centre, and Director of Robotic Services, at the CUHK Medical Centre. In 2021, he was awarded the Ten Outstanding Young Persons Award (Hong Kong) and the SIU-Innovators Award. In 2023, he was appointed as an Adjunct Professor at the Medical University of Vienna. In 2024, he received the World Chinese Urological Society Rising Star Award.

Jeremy is an oncological surgeon with primary interest in bladder cancer. Previously, he conducted a randomised trial comparing between bipolar and monopolar transurethral resection of bladder tumour (TURBT) and showed that bipolar TURBT was able to achieve a higher detrusor sampling rate than monopolar TURBT. He has also developed a global consensus statement on en bloc resection of bladder tumour (ERBT). A total of 99 statements reached consensus and they have become the standard reference for urologists practising en bloc resection globally. Recently, he published the results of the EB-StaR study, which is a multi-centre randomised trial demonstrating that ERBT could reduce the 1-year recurrence rate from 38.1% to 28.5% for patients with ≤3cm non-muscle-invasive bladder cancer (NMIBC). He is also leading a phase 2 clinical trial on modified en bloc resection for large bladder tumours (>3cm). He is currently serving as a panel member of the European Association of Urology (EAU) Guidelines on NMIBC and Upper Tract Urothelial Carcinoma. He is an active member of the Urothelial Cancer Working Party, EAU Young Academic Urologists, and he is dedicated to high-quality research work in this area.

Jeremy has received numerous research grants with a total funding of more than 10 million USD. He has published more than 400 articles in peer-reviewed journals such as European Urology, European Urology Oncology, European Urology Focus and Nature Reviews Urology. He was the Chairperson of the Younger Fellows Chapter of the College of Surgeons of Hong Kong (2019-2021), the Chair of the Young Fellows Chapter of the Hong Kong Academy of Medicine (2021-2022), and he has been the Director of the Lions Kidney Educational Centre & Research Foundation since 2017. He is also the founder of the UroSoMe (Urology Social Media) working group and he believes that social media plays an important role in the modern era of medicine.

Research Interests

• Urinary biomarkers for bladder cancer
• Tumour heterogeneity and molecular classification of bladder cancer
• Transurethral en bloc resection of bladder tumour
• Androgen deprivation therapy for prostate cancer
• Advanced robotic surgery for urological cancers

Additional Information

• Director of Urology Centre, CUHK Medical Centre
• Director of Robotic Services, CUHK Medical Centre
• Congress Chair, Societe Internationale d'Urologie (SIU)
• Director of the Lions Kidney Educational Centre & Research Foundation
• Member of the Committee on Promotion of Organ Donation, HKSAR
• Panel member of the EAU Guidelines on Non-Muscle-Invasive Bladder Cancer
• Panel member of the EAU Guidelines on Upper Tract Urothelial Carcinoma
• Council member of the Hong Kong Society of Transplantation
• Chairperson of the Younger Fellows Chapter of the College of Surgeons of Hong Kong (2019-2021)
• Chair of the Young Fellows Chapter, Hong Kong Academy of Medicine (2021-2022)
• Steering Committee Member of the Asian Urological Surgery Training & Education Group
• Founder of the UroSoMe (Urology Social Media) working group
• Consulting editor for European Urology
• Associate editor for European Urology Oncology

Selected Publications

1. Teoh JY, Cheng CH, Tsang CF, Li KJ, Cheng BK, Chan WH, et al. Transurethral En Bloc Resection Versus Standard Resection of Bladder Tumour: A Randomised, Multicentre, Phase 3 Trial. Eur Urol. 2024;86:103-11. (Impact factor: 25.3).
2. Powles T, Albiges L, Bex A, Comperat E, Grunwald V, Kanesvaran R, Kitamura H, McKay R, Porta C, Procopio G, Schmidinger M, Suarez C, Teoh J, de Velasco G, Young M, Gillessen S, clinicalguidelines@esmo.org EGCEa. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(8):692-706. (Impact factor: 56.7).
3. Teoh JY, MacLennan S, Chan VW, Miki J, Lee HY, Chiong E, Lee LS, Wei Y, Yuan Y, Yu CP, Chow WK, Poon DM, Chan R, Lai F, Ng CF, Breda A, Kramer MW, Malavaud B, Mostafid H, Herrmann T, Babjuk M. An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting. Eur Urol 2020. (Impact factor: 25.3).
4. Dyrskjot L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J, Theodorescu D. Bladder cancer. Nat Rev Dis Primers. 2023;9(1):58. (Impact factor: 79.0).
5. Teoh JY, Ong WLK, Gonzalez-Padilla D, Castellani D, Dubin JM, Esperto F, Campi R, Gudaru K, Talwar R, Okhunov Z, Ng CF, Jain N, Gauhar V, Wong MC, Wroclawski ML, Tanidir Y, Rivas JG, Tiong HY, Loeb S, UroSoMe Working G. A Global Survey on the Impact of COVID-19 on Urological Services. Eur Urol 2020. (Impact factor: 25.3).
6. Teoh JY, Huang J, Ko WY, Lok V, Choi P, Ng CF, Sengupta S, Mostafid H, Kamat AM, Black PC, Shariat S, Babjuk M, Wong MC. Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. Eur Urol 2020. (Impact factor: 25.3).
7. Teoh JY, Castellani D, Mercader C, Sierra A, Heldwein FL, Chan EO, Wroclawski ML, Sepulveda F, Cacciamani GE, Rivas JG, Murphy DG, van Oort IM, Loeb S, Ribal MJ. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Eur Urol. 2021. (Impact factor: 25.3).
8. Teoh JY, Bhatt NR, Cucchiara V, Garcia Rojo E, Gauhar V, Mercader C, et al. Best Practice in Using Social Media: The European Association of Urology Position Statement. Eur Urol. 2024. (Impact factor: 25.3).
9. Liu AQ, Chiu PK, Yee SC, Ng CF, Teoh JY. SARS-CoV-2 infection correlates with male benign prostatic hyperplasia deterioration. J Intern Med. 2023;294(6):775-83. (Impact factor 11.1)
10. Bhatt NR, Garcia Rojo E, Gauhar V, Mercader C, Cucchiara V, Bezuidenhout C, van Gurp M, Bloemberg J, Teoh JY, Ribal MJ, Giannarini G, European Association of Urology Guidelines Office Dissemination C. The Intersection of Artificial Intelligence and Social Media in Shaping the New Digital Health Frontier: Powers and Perils. Eur Urol. 2024;85(3):183-4. (Impact factor: 25.3).
11. Eppler M, Ganjavi C, Ramacciotti LS, Piazza P, Rodler S, Checcucci E, Gomez Rivas J, Kowalewski KF, Belenchon IR, Puliatti S, Taratkin M, Veccia A, Baekelandt L, Teoh JY, Somani BK, Wroclawski M, Abreu A, Porpiglia F, Gill IS, Murphy DG, Canes D, Cacciamani GE. Awareness and Use of ChatGPT and Large Language Models: A Prospective Cross-sectional Global Survey in Urology. Eur Urol. 2024;85(2):146-53. (Impact factor: 25.3).
12. Bhatt NR, Teoh JY, Garcia Rojo E, Gauhar V, Mercader C, Cucchiara V, Bezuidenhout C, Rogers E, Ribal MJ, Giannarini G, European Association of Urology Guidelines Office Dissemination C, the European Association of Urology Patient O. Social Media Interventions for Patients and Public: Opportunities and Challenges for the Urology Community. Eur Urol. 2023;84(6):523-6. (Impact factor: 25.3).
13. Rodriguez Socarrás M, Loeb S, Teoh JY, Ribal MJ, Bloemberg J, Catto J, N’Dow J, Van Poppel H, Gómez Rivas J. Telemedicine and Smart Working: Recommendations of the European Association of Urology. Eur Urol 2020. (Impact factor: 25.3).
14. Wong SH, Teoh JYC, Leung CH, Wu WK, Yip BHK, Wong MC, Hui DS. COVID-19 and Public Interest in Face Mask Use. Am J Respir Crit Care Med 2020. (Impact factor: 19.3).
15. Chiu PK, Ng CF, Semjonow A, Zhu Y, Vincendeau S, Houlgatte A, Lazzeri M, Guazzoni G, Stephan C, Haese A, Bruijne I, Teoh JY, Leung CH, Casale P, Chiang CH, Tan LG, Chiong E, Huang CY, Wu HC, Nieboer D, Ye DW, Bangma CH, Roobol MJ. A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings. Eur Urol 2019; 75(4):558-561. (Impact factor: 25.3).

The full list of publications can be accessed here.